Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

Fujimura, T; Yamashita-Kashima, Y; Kawasaki, N; Yoshiura, S; Harada, N; Yoshimura, Y

Yamashita-Kashima, Y (corresponding author), Chugai Pharmaceut Co Ltd, Prod Res Dept, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.

MOLECULAR CANCER THERAPEUTICS, 2021; 20 (6): 1133

Abstract

Follicular lymphoma commonly recurs and is difficult to cure. Obinutuzumab is a humanized glycoengineered type II anti-CD20 antibody with a mode of ac......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索